GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eledon Pharmaceuticals Inc (FRA:2TK) » Definitions » Buyback Yield %

Eledon Pharmaceuticals (FRA:2TK) Buyback Yield % : -18.08 (As of Dec. 11, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Eledon Pharmaceuticals Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Eledon Pharmaceuticals's current buyback yield was -18.08%.


Eledon Pharmaceuticals Buyback Yield % Historical Data

The historical data trend for Eledon Pharmaceuticals's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eledon Pharmaceuticals Buyback Yield % Chart

Eledon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -123.22 -4.00 - - -76.25

Eledon Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -0.01 -194.92 -21.21

Competitive Comparison of Eledon Pharmaceuticals's Buyback Yield %

For the Biotechnology subindustry, Eledon Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eledon Pharmaceuticals's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eledon Pharmaceuticals's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Eledon Pharmaceuticals's Buyback Yield % falls into.



Eledon Pharmaceuticals Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Eledon Pharmaceuticals's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 30.277) / 39.709484
=-76.25%

Eledon Pharmaceuticals's annualized Buyback Yield for the quarter that ended in Sep. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 4.76) * 4 / 89.779158
=-21.21%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Sep. 2024) data.


Eledon Pharmaceuticals Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Eledon Pharmaceuticals's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Eledon Pharmaceuticals Business Description

Traded in Other Exchanges
Address
19900 MacArthur Boulevard, Suite 550, Irvine, CA, USA, 92612
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Eledon Pharmaceuticals Headlines

No Headlines